VAPOR 2 Study Pivotal Study Clinical Protocol/Frye/IUGUP23019
Basic Study Information
Purpose:
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water
Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2
(GGG2) localized intermediate-risk prostate cancer.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Thomas Frye
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search